Surgical outcomes in patients who received presurgical treatment with pazopanib for advanced renal cell carcinoma with inferior vena cava tumor thrombus; a historical control study

Surgical outcomes in patients who received presurgical treatment with pazopanib for advanced renal cell carcinoma with inferior vena cava tumor thrombus; a historical control study - Surgical outcomes in patients who received presurgical treatment with pazopanib for advanced renal cell carcinoma with inferior vena cava tumor thrombus; a historical control study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034799

Enrollment

Registered

2018-12-01

Start date

2018-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal cell carcinoma

Interventions

12 weeks oral administration of pazopanib. Surgical excision of tumor and thrombus within 7 days and 21 days from the end date of pazopanib administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Renal cell carcinoma with tumor thrombus 2.Tumor thrombus which reach Inferior vena cava 3.Written informed consent

Exclusion criteria

Exclusion criteria: 1.Patients who did not participate in this study 2.Patients who participated in other clinical trials within 4 months. 3.Performance Status> 3 4.AST,ALT> 3.0*upper limit of normal range(ULN), or total Bil> 2.0*ULN 5.Patients who receive treatment of other cancer

Design outcomes

Primary

Measure	Time frame
bleeding volume in surgery	—

Secondary

Measure	Time frame
-Improvement of surgical invasion: Outcome of change from surgical procedure expected before surgery to minimally invasive surgical procedure due to tumor reduction. -Operation time -Grade 3 or higher complications -Reduction in the level of tumor embolism according to the classification of Mayo clinic -Reduction rate of primary tumor and metastatic lesion.	—

Countries

Japan

Contacts

Public ContactYasuyoshi Okamura

Kobe university Graduate School of Medicine Urology

dfgky008@gmail.com0783826155

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026